Status:
TERMINATED
TDCS and Aphasia Therapy in the Acute Phase After Stroke
Lead Sponsor:
University Hospital, Ghent
Conditions:
Aphasia Following Cerebral Infarction
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
This study evaluates the neuromodulatory effect of combined tDCS and aphasia therapy in patients in the acute stage after stroke. Half of the participants will receive aphasia therapy and tDCS, the ot...
Detailed Description
Aphasia is present in about one third of all stroke patients in the acute phase. The first few months after stroke, considerable spontaneous recovery is initiated, including neuronal plasticity and re...
Eligibility Criteria
Inclusion
- Diagnosed with mild-moderate aphasia (Token Test Score between 7 and 40)
- Inclusion in the first few days after stroke (acute phase)
- Age 18 - 85 years
- Being right-handed
- Mothertongue: Dutch
- Able to undergo functional and specific linguistic testing and therapy in the acute phase following stroke
- Imaging (CT or MRI) prior to inclusion (standard of care)
- Signed Informed Consent
Exclusion
- History of other diseases of the central nervous system, psychological disorders and (developmental) speech and or language disorders
- Serious non-linguistic, cognitive disorders (as documented in the patients' medical history and inquired in anamneses)
- Prior brain surgery
- Excessive use of alcohol or drugs
Key Trial Info
Start Date :
October 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2018
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03297450
Start Date
October 2 2017
End Date
March 30 2018
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ghent
Ghent, East-Flanders, Belgium, 9000